MoonLake Immunotherapeutics reported earnings results for the first quarter ended March 31, 2024. For the first quarter, the company reported net loss was USD 13.67 million compared to USD 9 million a year ago. Basic loss per share from continuing operations was USD 0.22 compared to USD 0.23 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
39.49 USD | -1.69% | -5.89% | -34.61% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-34.61% | 2.53B | |
+14.84% | 122B | |
+18.31% | 113B | |
+3.61% | 22.66B | |
-18.26% | 21.34B | |
-41.55% | 16.92B | |
-14.23% | 16.68B | |
-16.03% | 16.61B | |
-0.68% | 13.62B | |
+21.87% | 11.04B |
- Stock Market
- Equities
- MLTX Stock
- News MoonLake Immunotherapeutics
- MoonLake Immunotherapeutics Reports Earnings Results for the First Quarter Ended March 31, 2024